# A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer

> **NCT02054338** · PHASE3 · TERMINATED · sponsor: **Pierre Fabre Medicament** · enrollment: 1004 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Vinflunine+Gemcitabine
- **DRUG:** Paclitaxel+Gemcitabine

## Key facts

- **NCT ID:** NCT02054338
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2011-06
- **Final completion:** 2015-02
- **Target enrollment:** 1004 (ACTUAL)
- **Why stopped:** Study was stopped before progressive disease or death of alive subjects.
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02054338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02054338, "A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02054338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*